Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AKINETON (biperiden lactate) is an anticholinergic agent administered via injection for the management of extrapyramidal side effects associated with antipsychotic medications. It works by blocking cholinergic neurotransmission to counteract dopamine antagonism-induced movement disorders. This is a legacy small-molecule therapeutic with established clinical utility in psychiatric and neurological settings.
Product is in late lifecycle with minimal commercial expansion; commercial teams are typically lean and focused on retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on AKINETON offers limited career advancement within AbbVie due to zero linked job postings and approaching loss of exclusivity; roles are primarily defensive and operational rather than innovation-focused. This is a suitable position for professionals seeking stability in a legacy portfolio or those transitioning to post-LOE brand management.
Worked on AKINETON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.